Geron Corp Stock Price, News & Analysis

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options totaling 431,600 shares to newly hired employees as part of their employment incentives. The options, issued on February 17, 2021, have an exercise price of $1.99 per share, aligning with Geron's closing stock price on the grant date. The vesting period is set over four years, beginning with 12.5% at six months, followed by equal installments thereafter. This grant adheres to Nasdaq rules and is part of Geron's 2018 Inducement Award Plan.

Geron focuses on developing imetelstat, a telomerase inhibitor, in hematologic malignancies.

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 120,000 shares of common stock to newly hired employees as an employment inducement. The options were granted on January 20, 2021, with an exercise price of $1.74 per share, matching the closing stock price on the grant date. These options have a 10-year term and vest over four years. This action complies with Nasdaq Listing Rule 5635(c)(4) and aligns with Geron's 2018 Inducement Award Plan. Geron is focused on developing imetelstat, a telomerase inhibitor, in hematologic cancers.

Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on January 20 at 3:00 p.m. ET. The presentation will be accessible via a live audio webcast on Geron's website, with a replay available for 30 days post-event.

Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor targeting hematologic myeloid malignancies. For further details, visit www.geron.com.

Geron Corporation (Nasdaq: GERN) has announced the launch of the IMpactMF Phase 3 clinical trial for imetelstat, a telomerase inhibitor targeting refractory myelofibrosis (MF). This trial aims to enroll approximately 320 patients and assess the drug's ability to extend overall survival and improve symptoms, following promising Phase 2 results. The primary endpoint will focus on overall survival, with secondary endpoints covering various clinical outcomes. The trial incorporates over 150 sites globally, though potential COVID-19-related delays are acknowledged.

Geron Corporation (Nasdaq: GERN) has achieved fifty percent enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). This milestone is crucial for advancing the trial, which aims to assess transfusion independence and disease-modifying effects of imetelstat. The trial is set to enroll approximately 170 patients, with top-line results expected in the second half of 2022, provided enrollment completes by mid-2021.

Imetelstat is the first telomerase inhibitor in development, offering a potential treatment alternative for MDS patients.

Geron Corporation (Nasdaq: GERN) announced multiple presentations at the 62nd ASH Annual Meeting, showcasing clinical data on imetelstat, their telomerase inhibitor. Key highlights include:

• 42% of patients in the IMerge Phase 2 trial achieved over 8-week red blood cell transfusion independence.
• Imetelstat showed potential disease-modifying activity in patients with relapsed/refractory myelofibrosis (MF), with significant reductions in mutation burden.
• Upcoming Phase 3 trials, IMerge and IMpactMF, aim to validate imetelstat’s efficacy in lower risk MDS and high-risk MF.

Geron Corporation (Nasdaq: GERN) announced presentations at the 62nd American Society of Hematology Annual Meeting, showcasing clinical data on imetelstat, its first-in-class telomerase inhibitor. Findings from the IMerge and IMbark Phase 2 trials evidence imetelstat’s disease-modifying activity and potential clinical benefits, particularly in lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF). Key results include 42% of MDS patients achieving durable transfusion independence and significant improvements in overall survival among MF patients.

Geron Corporation (Nasdaq: GERN) announced the grant of a non-statutory stock option for 80,000 shares of its common stock to a newly-hired employee. This option was issued on November 18, 2020, at an exercise price of $1.90 per share, matching the closing price on the grant date. The option has a 10-year term and vests over four years, beginning with a 12.5% vesting after six months and the rest in monthly installments. This action complies with Nasdaq Listing Rule 5635(c)(4) and pertains to Geron's 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN) announced that its CEO, John A. Scarlett, will present a company overview at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. ET. A live audio webcast of the presentation will be accessible on Geron’s website, with an archived version available for 30 days post-event. Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor for hematologic myeloid malignancies. For more details, visit www.geron.com.